21 results about "Neurological dysfunction" patented technology

The invention relates to the technical field of nervous system dysfunction, in particular to a nerve regulation and control system for degenerative disease treatment based on multi-modal physiological feedback, which comprises a central processing unit, an optical radiation applicator, a mechanical vibration applicator, an integrated biological signal sensing array and a man-machine interaction module, cooperative stimulation is applied by using a multispectral light source and a broadband vibrator, and multi-dimensional physiological signals such as heart rate variability, myoelectricity, galvanic skin and the like are monitored in real time through a sensor array. A multi-parameter adaptive control algorithm built in the central processing unit can dynamically and intelligently adjust stimulation parameters based on the feedback signals to form an accurate personalized treatment closed loop. Meanwhile, the safety monitoring module based on the biological thermal model ensures the safety boundary of the treatment process. According to the invention, intelligent, self-adaptive and non-invasive treatment of nerve dysfunction is realized.

A rehabilitation evaluation system for a patient with central nervous system dysfunction comprises the following steps of S1, collecting videos, motion data and pressure data of a user through a data collection layer, S2, uploading the video data to an edge computing server, performing preliminary posture estimation, and S3, performing rehabilitation evaluation. The method comprises the following steps: S1, carrying out edge calculation on the data, S3, transmitting the data subjected to edge calculation to a cloud server for deep modeling analysis of gait and balance parameters, S4, carrying out abnormal mode identification and comparison after parameter analysis, S5, uploading the analyzed data after comparison to a decision application layer, S6, transmitting each parameter and a corresponding processing scheme to a doctor end for a doctor to check, and S5, carrying out data processing. The method has the advantages that through full-link innovation of multi-mode lightweight acquisition, edge cloud hierarchical processing, double-model intelligent diagnosis, reinforcement learning dynamic optimization and visual remote decision, central nervous rehabilitation evaluation extends to a daily life scene from a laboratory, and core breakthrough of precision improvement, efficiency multiplication and personalized enhancement is achieved.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The present technology provides systems and methods for delivering electrical stimulation having relatively long pulse widths to a patient’s spinal cord region to treat autonomic nervous system dysfunction. For example, some embodiments include delivering an electrical therapy signal having individual pulses with pulse widths of between about 2 milliseconds and about 10 seconds. The electrical therapy signals may treat autonomic nervous system dysfunction by normalizing activity of the patient’s parasympathetic nervous system, normalizing activity of the patient’s sympathetic nervous system, and / or normalizing a balance of activity between the patient’s parasympathetic and sympathetic nervous systems.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

Indazole compounds which are useful as allosteric potentiators / positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.

The present technology provides systems and methods for delivering electrical stimulation having relatively long pulse widths to a patient’s spinal cord region to treat autonomic nervous system dysfunction. For example, some embodiments include delivering an electrical therapy signal having individual pulses with pulse widths of between about 2 milliseconds and about 10 seconds. The electrical therapy signals may treat autonomic nervous system dysfunction by normalizing activity of the patient’s parasympathetic nervous system, normalizing activity of the patient’s sympathetic nervous system, and / or normalizing a balance of activity between the patient’s parasympathetic and sympathetic nervous systems.

The application provides a kind of affected side spatial stratification activation and multi-modal unilateral spatial neglect (USN) cognitive function evaluation and training intelligent system, aiming at solving the pain points such as low efficiency of evaluation, training homogeneity, effect difficult to transfer in USN patient rehabilitation, and building a whole-process intelligent rehabilitation system of "accurate evaluation-personalized training-dynamic optimization-effect transfer". Through the combination of rapid quantitative evaluation system, behavior data and electroencephalogram signal, the objective grading of USN severity is realized, which gets rid of artificial dependence and greatly improves the evaluation efficiency and accuracy; through the whole-process automatic operation and machine learning self-adaptive optimization, the operation cost of clinical personnel is reduced, the rehabilitation effect is traceable and evaluable, and an accurate and personalized intelligent rehabilitation system is built, which provides a whole-process solution for USN patients and has important significance for promoting the intelligent development of post-stroke neurological dysfunction rehabilitation.

The application provides application of IL-17A as a target point in preparation of a drug for screening treatment or prevention of cardiac arrest. The application also provides application of IL-17A as a target point in preparation of a monoclonal antibody drug for screening treatment or prevention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving post-cardiac arrest syndrome. The application provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for early intervention of cardiac arrest. The application also provides application of an anti-IL-17A monoclonal antibody in preparation of a drug for improving myocardial injury, cardiac dysfunction, brain injury or neurological dysfunction caused by cardiac arrest. The application also provides application of a reagent for detecting IL-17A level in serum in preparation of a kit for detecting a myocardial infarction combined with cardiac arrest patient. The application proves by experiments that IL-17 related pathways in heart and brain tissues are significantly activated after cardiac arrest, and IL-17A in serum is significantly increased, and early antagonism of IL-17A by using an IL-17A monoclonal antibody after resuscitation can improve myocardial injury, cardiac dysfunction (systolic and diastolic dysfunction), brain tissue injury or neurological dysfunction after cardiac arrest, and improve survival rate after cardiac arrest.

The invention provides a method of determining whether a subject has a neurological dysfunction associated with a signal in a particular electroencephalogram (EEG) or magnetoencephalogram (MEG) frequency range, the method comprising: obtaining an EEG power spectrum from the subject; and obtaining a metric quantifying the magnitude of power in particular frequency range metric quantifying the power in the power spectrum in the particular frequency range, wherein the metric summarises the power in said frequency range corrected using an estimate of the power in said frequency range that is attributable to background signal that is specific to said frequency range, wherein the metric is indicative of the presence and / or severity and / or direction of a neurological dysfunction. Related methods and devices are also described.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of Yulangsan, 5-30 parts of panax japonicus, 5-30 parts of ruta graveolens, 5-30 parts of camphorwood, 5-30 parts of millettia japonica, 5-30 parts of costus root, 5-30 parts of rhizoma curculiginis, 5-30 parts of clinopodium herb, 5-30 parts of white hyacinth bean and 5-30 parts of radix puerariae. The whole formula treats both qi and blood, regulates phlegm and blood stasis, is reasonable in compatibility of the medicines, and has the effects of tonifying qi and activating blood, dispersing blood stasis and dredging collaterals, clearing heat and dissipating blood stasis, restoring consciousness and dredging collaterals, and tonifying spleen and warming kidney. The traditional Chinese medicine composition can relieve cerebral infarction and encephaledema, improve neurological dysfunction, inhibit neuronal apoptosis and regulate inflammatory response to relieve inflammatory damage of brain tissue, and a good treatment effect on cerebral arterial thrombosis model rats is achieved. The traditional Chinese medicine composition provides a new choice for development of medicines for treating cerebral arterial thrombosis.

The invention relates to the technical field of medical animal disease models, in particular to a method for establishing a gene point mutation non-human primate model.According to the method, editing is conducted through a CRISPR / Cas9 gene editing system, and finally a non-human primate model carrying CHD8c.3724Cgt is obtained; according to the cynomolgus monkey with T (p.Arg1242Ter) point mutation, different types of point mutations occur at the 3724th basic group of the CHD8 gene, the mutation of T enables arginine (Arg) at the 1242nd site to be replaced by a termination codon to form truncated protein, so that the dosage of CHD8 protein haploid coded by the gene is insufficient. The animal model for simulating human CHD8 mutation related nervous system diseases is constructed and can be used as an ideal research model for researching autism related phenotypes caused by insufficient haplodose, and a foundation is laid for revealing a neurological dysfunction mechanism and exploring a potential treatment strategy.

The present technology provides systems and methods for delivering electrical stimulation having relatively long pulse widths to a patient’s spinal cord region to treat autonomic nervous system dysfunction. For example, some embodiments include delivering an electrical therapy signal having individual pulses with pulse widths of between about 2 milliseconds and about 10 seconds. The electrical therapy signals may treat autonomic nervous system dysfunction by normalizing activity of the patient’s parasympathetic nervous system, normalizing activity of the patient’s sympathetic nervous system, and / or normalizing a balance of activity between the patient’s parasympathetic and sympathetic nervous systems.

The inventors found that BIND, psychiatric diseases with jaundice and psychiatric diseases caused by UGT1A1 gene mutation of a subject can be treated, prevented or controlled by administering a 5-HT1A / 1B receptor agonist to the subject. Therefore, the present disclosure provides a pharmaceutical composition, including a 5-HT1A / 1B receptor agonist, for the treatment, prevention or control of BIND, psychiatric disorders with jaundice, and psychiatric disorders caused by UGT1A1 gene mutation.

The APRIL study demonstrated that infusion of ApTOLL 0.2 mg / kg (SEQ ID NO: 1) in combination with endovascular treatment in selected stroke patients was safe and reduced mortality at 90 days. ApTOLL was demonstrated to limit the occurrence of intracranial hemorrhage and reperfusion injury that can occur after recanalization, and also improve early neurological dysfunction and long-term disability. The ApTOLL molecule is provided for use in reducing the risk of intracranial hemorrhage or secondary hemorrhage, reducing neurological damage, and improving neurological recovery after acute ischemic stroke in subjects.

The invention discloses an application of a pro-CTSD inhibitor or antibody in cerebral arterial thrombosis, belongs to the technical field of gene functions and application, and discloses an application of pro-CTSD as a therapeutic target in screening a biological preparation for treating secondary inflammation of cerebral arterial thrombosis. The invention finds that pro-CTSD can aggravate the phenomena of brain injury and neurological dysfunction by enhancing the adhesion effect of cerebral vascular endothelial cells. The invention also finds that by down-regulating the plasma pro-CTSD level, the cerebral injury of the cerebral arterial thrombosis can be alleviated, the neurological dysfunction is improved, and an effective therapeutic target is provided for developing the cerebral arterial thrombosis.

The invention belongs to the technical field of medicine preparation, and particularly relates to application of hypoglycosylated apolipoprotein D in preparation of a medicine for repairing a blood brain barrier. Experiments in the invention show that in the molecular level, the binding affinity of low glycosylated apolipoprotein D (ApoD) and CD36 is increased by about 9 times compared with that of high glycosylated apolipoprotein D, and a key mechanism foundation is laid for function exertion; in an MCAO (middle cerebral artery occlusion) stroke model (middle cerebral artery occlusion model), the hypoglycosylated apolipoprotein D can remarkably repair a capillary structure, reduce an infarct area, improve neurological dysfunction, reduce blood-brain barrier permeability and enhance capillary perfusion, and the treatment efficiency is far superior to that of the hyperglycosylated apolipoprotein D; aiming at an elderly stroke model, the hypoglycosylated ApoD can improve the survival rate of mice, repair disordered and expanded capillaries, inhibit pathological endothelial cell proliferation and strengthen the integrity of a blood-brain barrier, and the hypoglycosylated ApoD can still continuously improve neurological functions and vascular phenotypes 30 days after stroke.

The application provides a flexible adherable implantable multi-site precise electrical stimulation system and a preparation method thereof, and belongs to the technical field of flexible electrode preparation. The application comprises a flexible substrate and a package, which is internally printed with a continuous stretchable liquid metal gallium-indium conductor; double-sided adhesive hydrogel with double-interface chemical modification, which is covalently adhered to the flexible packaging material and biological tissue respectively; an external electrical stimulation conductor connected with the liquid metal gallium-indium conductor, and the liquid metal conductive network contains stimulation sites that can precisely stimulate different segments of the ventral and dorsal spinal cord. The application first combines the double-network hydrogel with covalent bonding effect with the flexible electrode prepared based on liquid metal gallium-indium, realizes stable adhesion of the double-interface of the flexible electrode and the tissue, greatly improves the long-term implantation stability, can realize precise stimulation of the ventral and dorsal bilateral multi-site of the epidural spinal cord, and provides a new instrument support for the treatment of spinal cord-related neurological dysfunction.

The application of β-asarone ether in the preparation of drugs for promoting myelin regeneration, for improving neurological dysfunction in organisms with myelin injury, inhibiting inflammatory demyelination in the central nervous system, and enhancing memory and cognitive function.

The invention relates to a traditional Chinese medicine component compound. The traditional Chinese medicine component compound comprises baicalin, salidroside and catalpol. The traditional Chinese medicine component compound disclosed by the invention is a traditional Chinese medicine compound, pays attention to enhancement of an autoimmune system, and is free of toxic and side effects and reasonable in formula; the traditional Chinese medicine composition effectively aims at main pathogenesis of ischemic encephaledema and cerebral ischemia, such as reduction of cerebral moisture content, reduction of cerebral ischemia area, alleviation of neurological dysfunction, reduction of neuronal apoptosis and the like, and has a remarkable curative effect; the raw materials are wide in source and easy to obtain, can be extracted and biosynthesized by adopting crude drugs, can also be directly used as chemical synthesis products, and are convenient for preparation and large-scale production.